Basal Cell Carcinoma (Epithelioma) Therapeutic Pipeline H2 2014 Review Research Report

DALLAS, December 6, 2014 /PRNewswire/ --

RnRMarketResearch.com adds "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014" therapeutic market research report of 77 pages with latest updates, data and information to its online business intelligence library.

The Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review, H2 2014 report provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review, H2 2014 report covers a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma), review of key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities as well asreview of key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects and provides a review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages along with a detailed assessment of monotherapy and combination therapy pipeline projects is provided.  Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are covered. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=248261 .

Major Points from Table of Contents for Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014 report include:

Introduction 7
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8
Therapeutics Development 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis 10
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies 11
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Investigation by Universities/Institutes 13
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies 17
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Investigation by Universities/Institutes 18
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development 19
4SC AG 19
Biofrontera AG 20
Biosceptre International Limited 21
Bristol-Myers Squibb Company 22
Genextra S.p.a. 23
InMed Pharmaceuticals Inc. 24
Mayne Pharma Group Limited 25
MediGene AG 26
Novartis AG 27
Oncovir, Inc. 28
Transgene SA 29
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
R&D Progress 60
Small Molecules to Inhibit Casein Kinase 1 for Cancer - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Basal Cell Carcinoma (Basal Cell Epithelioma) - Recent Pipeline Updates 62
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects 71
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products 72
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones 73
Featured News & Press Releases 73
Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014 73
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 73
Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma 74
Feb 19, 2014: Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables 

List of Figures 

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Explore more reports on the pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
[email protected]

SOURCE RnR Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED